DermBiont, a Boston, MA-based clinical stage therapeutics company dedicated to the discovery and development of live bacterial products for the treatment of skin diseases, closed an $8M Series A funding.
The round was led by Zola Global Investors, Toba Capital, and Viking Global Investors. Mark de Souza, Ph.D., CEO of Chromaderm and Interim CEO of Wings Therapeutics, also participated in the round.
The financing proceeds will be used to fund ongoing clinical trials and discovery.
Co-founded in 2017 by Karl Beutner, M.D., Ph.D., Robert Brucker, Ph.D, and Nichola Eliovits, DermBiont is leveraging skin microbiome therapeutics to advance its lead live bacterial product, DBI-001, in clinical trials for the treatment of fungal skin infections, beginning with interdigital athlete’s foot, moccasin athlete’s foot, and onychomycosis.
In addition, the company has a discovery platform based on a library of over 5,000 microbes isolated from human skin and a large data set of Nextgen sequencing of the human microbiome across healthy and diseased skin.
DermBiont was incubated and funded by Olive Tree Capital until joining the 7th cohort of the Illumina Accelerator program in mid-2018.